Researchers have identified a single protein whose removal transforms immune cells into far more lethal cancer fighters. By blocking Ant2, scientists discovered they could rewire how T cells generate and consume energy, fundamentally upgrading the body's natural tumor-killing machinery.
The finding, published in Nature Communications, suggests a direct path toward more powerful immunotherapies. An international team led by PhD student Omri Yosef and Prof. Michael Berger of Hebrew University's Faculty of Medicine worked with collaborators at Philipps University of Marburg and the University of Texas MD Anderson Cancer Center to unlock this metabolic secret.
The core insight is elegantly simple: when T cells are forced to alter their energy metabolism, they become dramatically better at detecting and destroying cancer cells. "By disabling Ant2, we triggered a complete shift in how T cells produce and use energy," explains Prof. Berger. "This reprogramming made them significantly better at recognizing and killing cancer cells."
The research centers on mitochondria, the cellular power plants where energy conversion happens. When scientists disrupted a specific energy pathway inside T cells, they essentially rewired the cells' internal engines, placing them in a heightened state of readiness. The modified cells showed improved endurance, multiplied more rapidly, and targeted tumors with greater precision than their unmodified counterparts.
What makes this discovery particularly significant is its translational potential. The metabolic shift can be triggered not only through genetic engineering but also with pharmaceutical drugs. That distinction matters enormously for moving from laboratory mice to human patients. Rather than requiring complex genetic modifications, doctors might one day use a drug to trigger the same metabolic rewiring in patients' own immune cells.
This work reflects a broader shift in cancer immunotherapy, moving beyond simply guiding immune responses toward fundamentally upgrading how immune cells operate at the metabolic level. Rather than just telling immune cells to attack harder, researchers are now asking how to make them intrinsically more capable fighters.
Further studies and clinical trials remain necessary before these findings reach the clinic. But the potential is substantial. "By learning how to control the power source of our immune cells, we may be able to unlock therapies that are both more natural and more effective," Prof. Berger notes.
Author Jessica Williams: "A single protein controlling T cell metabolism could reshape cancer treatment, and the fact that drugs might do the job instead of genetic engineering makes this actually achievable in real patients."
Comments